Aims: This multicentre, randomized, double-blind study investigated the efficacy and safety of gemigliptin in Korean type 2 diabetes mellitus (T2DM) patients with moderate to severe renal impairment (RI).
Funding information
LG Life Sciences, Seoul, Republic of Korea coordinated and funded this study [Correction added on 9 August 2017, after first online publication: Affiliation 4 was previously incorrect and has been amended in this version]. Albuminuria, a marker for diabetic nephropathy, is an independent predictor of stroke and cardiovascular risks, 4, 5 which implies that diabetes patients with renal impairment (RI) are at increased risk of stroke and cardiovascular diseases. Thus, glycaemic control is fundamental for diabetes management; however, pharmacotherapy options in diabetes patients with RI are rather limited because of the risk of accumulation of certain drugs and/or their metabolites resulting from a reduced glomerular filtration rate (GFR). Thereby, certain drugs -most of the first-generation sulfonylureas, glyburide or alpha-glucosidase inhibitors -are contraindicated. [6] [7] [8] [9] Meanwhile, all available dipeptidyl peptidase-4 (DPP-4) inhibitors can be used in this population, with or without dose modification, and they showed good tolerability, low risk of hypoglycaemia and neutral effect on body weight. These agents have recently gained interest as a treatment for type 2 diabetes mellitus (T2DM) patients with RI, based on experimental evidence of their renoprotective effects, such as reduction of albuminuria, in addition to their antiglycaemic effects. 10 Gemigliptin, a DPP-4 inhibitor, was also examined for such an effect in a mice model of diabetic nephropathy. 11 In this study, we primarily aimed to confirm the efficacy and safety of gemigliptin in T2DM patients with moderate to severe RI. Additionally, we planned to assess whether the beneficial effects of gemigliptin observed in the aforementioned animal model would be reproduced in the clinical setting by investigating the effects of gemigliptin on albuminuria, estimated GFR (eGFR) and urinary biomarkers.
| INTRODUCTION
Hyperglycaemia
| MATERIALS AND METHODS

| Study design
This multicentre, randomized, double-blind study comprised the 12-week main part (placebo vs gemigliptin) and the 40-week extension (linagliptin switched from placebo vs gemigliptin) (ClinicalTrial.gov registration no. NCT01968044). Here we report the results of the main part.
After 2 weeks of a placebo run-in period, eligible patients were randomized to the gemigliptin group or placebo group in a 1:1 ratio with stratification by severity of RI and the type of background antidiabetic agents. Randomization codes were generated by a statistician using SAS software version 9.2 (SAS Institute, Cary, North Carolina) and we used the interactive web response system (IWRS) for randomization.
The double-blind approach was maintained by providing matching placebo, labelling each study drug with a kit number, disclosing the randomization code only to authorized personnel (statistician, IWRS manager and randomization manager) when necessary, and by not disclosing individual data to the investigator or other studyrelated personnel during or before the time of this interim analysis.
The study was conducted in compliance with the Declaration of Helsinki, Good Clinical Practice guidelines and standard operating procedures of the sponsor. The study was approved by the institutional review board of each investigational site, and written informed consent was obtained before the screening procedure. 
| Study subjects
| Study interventions
After a 2-week placebo run-in period, patients were randomized to receive gemigliptin 50 mg qd or matching placebo for 12 weeks. As background medications, only insulin and/or sulfonylurea were allowed, if prescribed for more than 6 weeks before screening. Other drugs affecting blood glucose level were prohibited during the study unless indicated as rescue therapy, which was regarded as a protocol violation.
Patients receiving rescue therapy could remain in the study at the investigator's discretion unless rescue therapy lasted for more than 2 weeks. 
| Efficacy and safety assessments
| Statistical analyses
Primary objective was to prove the superiority of gemigliptin to placebo in terms of HbA1c change at week 12. Assuming an SD of 1.21% (13.2 mmol/mol) for HbA1c change, a total of 110 patients was considered sufficient to achieve 80% power to detect between-group difference with a one-sided significance level of 2.5%. Demographics and baseline characteristics were comparable between groups ( Approximately 61% of the patients had macroalbuminuria and 24%
had microalbuminuria. Over 90% of the patients received background antidiabetic treatment with insulin (52%) or sulfonylurea (31%) or a combination of both (11%). Common concurrent medical conditions included chronic kidney disease (86%), hypertension (79%), hyperlipidaemia (28%), dyslipidaemia (15%) and hypercholesterolemia (9%).
The distribution of concurrent medical conditions and concomitant medications was similar between groups. The mean exposure to study drug was 81 and 80 days in the gemigliptin and placebo groups, respectively. Table 2 . After 12 weeks of treatment, glycated albumin and fructosamine significantly decreased in the gemigliptin group (P < .001) but not in the placebo group, and the between-group
| Efficacy
Mean HbA1c values (A) during study period and mean change from baseline at week 12 in subgroups according to severity of RI (B). Error bars represent 95% CI; *P < .001, paired t-test; #P < .001, Wilcoxon signed rank test represents significant decrease from baseline; **P < .001, ANCOVA; ##P < .001, two-sample t-test; ###P < .05, Wilcoxon rank sum test represents significant difference from placebo. A, Gemigliptin significantly decreased HbA1c at both week 6 and week 12 (P < 0.001). B, The degree of HbA1c change did not differ between the 2 subgroups according to the severity of RI.
differences were all significant. No significant changes were observed in body weight and fasting serum C-peptide in both groups. With regard to indexes for insulin resistance and beta cell function, HOMA-beta was significantly improved from baseline only in the gemigliptin group compared to the placebo group (P < .001), and no meaningful change was observed in HOMA-IR. Among the fasting lipid parameters, total cholesterol and LDL cholesterol decreased significantly only in the gemigliptin group, and the degree of change was significant compared with that in the placebo group (P = .006 for total cholesterol, P = .030 for LDL cholesterol). UACR (mg/g creatinine) significantly decreased in the gemigliptin group (P < .001; Table 2 ), and this change was more prominent in patients with macroalbuminuria than in those with microalbuminuria ( Figure S2 , Supporting Information). Exploratory analysis showed a significant decrease in urine nephrin in the gemigliptin group compared with the placebo group (median change at week 12, −0.03 vs −0.28, P < .001).
Pearson's correlation analysis confirmed the positive relationship between UACR and nephrin changes at week 12 ( Figure 2 ). The degree of UACR change did not differ between subgroups of patients divided by the extent of HbA1c change, systolic blood pressure change ( Figure 3 ) and concomitant use of renin-angiotensinaldosterone system (RAAS) inhibitors (Table S2 , Supporting Information). Spearman's correlation analysis also showed that the UACR decrease observed in the gemigliptin group was not correlated with the changes in HbA1c (P = −.068, P = .607) or systolic blood pressure (P = .201, P = .126). No significant changes were observed in urine 8-OHdG, type IV collagen or serum CRP, except that the mean level of type IV collagen in the gemigliptin group was significantly lower compared with that in the placebo group at week 12 ( Figure 2 ). Meanwhile, eGFR (mL/min/1.73 m 2 ) reduction was greater in the gemigliptin group than in the placebo group (median change at week 12, 0.00 vs −2.00, P = .015). Data are from the FAS and are presented as mean AE SD except UACR and HOMA-beta, which are presented as median (min, max); data for week 6 or week 12 represent the between-group difference.
| Safety
During the placebo run-in period, 17 patients experienced 19 AEs (Table S1 , Supporting Information). The incidence of treatmentemergent adverse events (TEAEs) was insignificantly higher in the placebo group compared with that in the gemigliptin group (50% vs 36%). In the gemigliptin group, the incidence of TEAEs was slightly higher among patients with severe RI than among those with moderate RI (44% vs 33%), and this tendency was more obvious in the placebo group (66% vs 35%, respectively). The most common AEs (≥5%) were hypoglycaemia (gemigliptin, 11% vs placebo, 8%) and nasopharyngitis (6% in both groups). No severe hypoglycaemia requiring corrective action was reported, and all cases of hypoglycaemia (10 cases in 7 patients with gemigliptin; 9 cases in 5 patients with placebo) except 1 case in the gemigliptin group were captured as adverse drug reactions (ADRs). The hypoglycaemia event not reported as an ADR in the gemigliptin group occurred in a patient who was receiving insulin as background medication, and the event was a transient hypoglycaemia. Other than the symptomatic hypoglycaemia reported as a TEAE, 3 cases of asymptomatic hypoglycaemia (plasma glucose < 70 mg/dL) were reported in 3 patients (2 receiving gemigliptin and 1 receiving placebo). The incidence of ADRs was similar between groups (gemigliptin, 15%; placebo, 12%); none of the ADRs was severe, and most cases were mild (gemigliptin, 11/13 events; placebo, 9/12 events; Table S1 , Supporting Information). Overall, 8 serious adverse events (SAEs) were reported (gemigliptin, 3; placebo, 5);
Urinary biomarkers for renal function. Error bars represent 95% CI; *represents significant decrease from baseline (P < .001, Wilcoxon signed rank test); **represents significant difference from placebo (P < .001, Wilcoxon rank sum test). A and B, UACR and nephrin decreased significantly from baseline at week 12 in the gemigliptin group and these changes differed significantly compared to the placebo group. C, Mean level of type IV collagen in the gemigliptin group was significantly lower compared to the placebo group at week 12. D, Pearson correlation analysis showed a positive relationship between UACR and nephrin changes at week 12. none was related to the study drug, and 1 patient with an SAE of spondylitis, which occurred on baseline, died following orthopaedic surgery (Table S3 , Supporting Information). AEs that caused early withdrawal were reported only in the placebo group: cerebral infarction (causality not related) and hyperglycaemia (causality possible). No clinically significant changes were noted in vital signs, haematology, serum chemistry and urinalysis.
| DISCUSSION
Gemigliptin 50 mg significantly reduced HbA1c in T2DM patients with moderate to severe RI, thus demonstrating its superiority to placebo.
Although HbA1c generally shows good correlation with glucose concentrations, the relationship in diabetes patients with RI is confounded by many factors such as the RBC lifespan, the uremic milieu, blood transfusions and use of erythropoietin stimulating agents. [13] [14] [15] Despite the ongoing argument about the validity of HbA1c as a glycaemic control marker in patients with RI, 16 HbA1c has been used as the preferred marker of glycaemic control in this population. 17 Recognizing this controversy, we also investigated alternative parameters such as glycated albumin and fructosamine, which all significantly decreased from baseline in the gemigliptin group but not in the placebo group. Aside from its beneficial effect on glycaemic control, our findings suggest that gemigliptin may also reduce UACR and urinary nephrin excretion, thus exerting a renoprotective effect. Furthermore, gemigliptin was well tolerated, and treatment was not associated with additional risk of hypoglycaemia or body weight change in this vulnerable population.
Considering the limited availability of therapeutics for T2DM patients with RI, the findings from this study have important clinical
implications. First, we demonstrated that gemigliptin does not require dose adjustment in patients with moderate to severe RI, which is consistent with the conclusion from the pharmacokinetic study in participants with normal renal function, mild RI (creatinine clearance
[CrCl] 50-80 mL/min), moderate RI (CrCl 30-50 mL/min), severe RI (<30 mL/min) or end-stage renal disease (on haemodialysis). 18 No dose adjustment of gemigliptin in patients with RI was proposed, on the basis of the exposure-response relationship and based on the fact that clearance of this agent was not affected by haemodialysis.
In this study, incidence of hypoglycaemia was similar to that with placebo (gemigliptin, 11%, placebo, 8%), as was observed in other studies of DPP-4 inhibitors in patients with RI. [19] [20] [21] Furthermore, the incidence of symptomatic hypoglycaemia in the gemigliptin group was similar to that in the placebo group (11% vs 8%, respectively) and most cases were of mild intensity (gemigliptin group, 10/11 cases vs placebo group, 8/9 cases). renoprotective effects in a type 1 diabetes animal model. 23, 24 In addition, saxagliptin limited renal hypertrophy, transforming growth factor beta-related fibrosis and nuclear factor-kBp65-mediated macrophage infiltration, supporting the improvement in tubulointerstitial profibrotic and inflammatory markers, 25 and chronic administration of lowdose sitagliptin attenuated glomerulosclerosis and tubulointerstitial and vascular kidney lesions in a model of T2DM/nephropathy. 26 The aforementioned evidence from animal models was further confirmed in a clinical setting; (1) 6-month treatment with sitagliptin and 12-week alogliptin therapy exerted an albuminuria-reducing effect in small uncontrolled studies 27, 28 and (2) linagliptin was shown to significantly reduce UACR at week 24 from baseline in a pooled analysis of 4 studies. 29 In a recent presentation of the MARLINA-T2D trial, however, linagliptin did not result in significant reduction in albuminuria in patients with RI (−6%; [95% CI, −15%, 3%]). 30 The different effect of linagliptin compared with gemigliptin on albumin excretion is unclear; however, linagliptin's renoprotective effect seems to be limited in early stages of glomerular damage as suggested by substudy analysis of MARLINA-T2D data showing that the diabetic nephropathy score, a composite score built from fitting several urinary biomarkers in DNlite to a statistical model, significantly decreased only in patients with UACR <300 mg/g creatinine (P < .05) but not in patients with UACR ≥300 mg/g creatinine. 31 More data are needed, however; overall, these data suggest that DPP-4 inhibitors seem to have a potential to decrease albuminuria, and probably display more complex renal protective properties.
Meanwhile, the decrease in eGFR observed in the gemigliptin group (median change at week 12, −2.00 mL/min/1.73 m 2 ) was statistically significant; however, the clinical significance of this change To conclude, in this multicentre, randomized, double-blind, phase III trial in Korean T2DM patients with moderate to severe RI, gemigliptin was well tolerated without dose modification for 12 weeks and was demonstrated to be superior to placebo in terms of glycaemic control. In the gemigliptin group, UACR significantly decreased in patients with microalbuminuria and macroalbuminuria, and urinary nephrin also significantly decreased compared with the placebo group, implying gemigliptin's potential renoprotective properties in this population, which requires further confirmation in future studies.
